Tevogen Bio Holdings Inc. (TVGN)
Automate Your Wheel Strategy on TVGN
With Tiblio's Option Bot, you can configure your own wheel strategy including TVGN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol TVGN
- Rev/Share 0.002
- Book/Share -0.0399
- PB -9.5134
- Debt/Equity -0.4
- CurrentRatio 0.3149
- ROIC 116.6207
- MktCap 75442563.0
- FreeCF/Share -0.0673
- PFCF -5.7175
- PE -2.3978
- Debt/Assets 0.6964
- DivYield 0
- ROE 3.9167
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | TVGN | D. Boral Capital | -- | Buy | -- | $10 | March 4, 2025 |
News
Tevogen CEO Donates Shares to Support Education for Underprivileged Children
Published: December 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced that its Founder and CEO, Dr. Ryan Saadi has made a charitable contribution of 230,000 shares of Tevogen common stock to SRLC USA, a United Nations-recognized 501(c)(3) nonprofit organization dedicated to serving underserved communities.
Read More
Tevogen CEO Donates Personal Shares to Support Local Fire Department
Published: December 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced that its Founder and CEO, Dr. Ryan Saadi has donated 50,000 shares of his personal holdings of Tevogen common stock to the Mt. Bethel Fire Company, supporting the organization's mission to protect the Warren Township community. The donations reflect Dr. Saadi's continued commitment to supporting first responders and the Warren Township community.
Read More
Tevogen CEO Supports Local Law Enforcement with Personal Contribution of 230,000 Company's Shares of Common Stock
Published: December 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced that its Founder and CEO, Dr. Ryan Saadi has donated 230,000 of his personal shares of common stock to the Warren Township Honorary Policemen's Benevolent Association (P.B.A.) Local 235.
Read More
Tevogen Celebrates Board Member Dr. Curtis Patton, Honored by Yale University for Distinguished Career and Lasting Contributions to Medical Education and Equity in Medicine
Published: December 09, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), is proud to recognize Curtis Patton, PhD, founding member of Tevogen's Board of Directors and Professor Emeritus at Yale University, as he is honored in a new joint portrait commissioned by the Yale School of Medicine's Program for Art in Public Spaces.
Read More
Tevogen Recognized on 2025 NJBIZ Power List Amid Growth and Multi-Billion-Dollar Revenue Outlook
Published: December 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced that it has been named to the 2025 New Jersey Power List by NJBIZ, recognizing the most influential organizations shaping New Jersey's economic and innovation landscape.
Read More
Tevogen Highlights Continued Capital Efficiency Following Filing of Q3 2025 Form 10-Q
Published: November 14, 2025 by: GlobeNewsWire
Sentiment: Neutral
Tevogen Bio highlights continued capital-efficient execution at a time when sustainability has become a defining challenge for the biotechnology industry.
Read More
Tevogen Reports Major Clinical Milestone: Expands HLA Coverage of its Investigational Precision T Cell Therapy for Acute and Long COVID
Published: November 05, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ), today announced a clinical milestone in the evolution of its proprietary ExacTcell™ platform: completion of T cell target identification for an additional five human leukocyte antigen (HLA) restrictions. This advancement significantly broadens the accessibility of Tevogen's investigational precision T cell therapies by extending therapeutic reach beyond the single HLA-A*02:01 restriction used in the Company's initial proof-of-concept (POC) clinical trial, the results of which were published in Blood Advances . That study demonstrated the safety and feasibility of Tevogen's third-party cytotoxic T lymphocyte …
Read More
Tevogen Clarifies Reported Financials, Highlighting Strong Capital Efficiency and Low Cash Burn
Published: November 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today issued a statement to provide clarity regarding its accumulated deficit reported under U.S. GAAP accounting standards in recent SEC filings.
Read More
Tevogen Senior Management Engages with Business and Community Leaders and Highlights Recent Progress
Published: October 29, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), in ongoing community, industry, and academic engagements, has continued to underscore its biopharma model centered on sustainability and patient affordability, highlighting the Company's significant progress toward making precision medicine accessible to all.
Read More
Tevogen Commends HHS for Addressing Long COVID, Emphasizes TVGN 489's Potential Impact for 20 Million Americans
Published: September 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today expressed its gratitude to the U.S. Department of Health and Human Services (HHS), Secretary Robert F. Kennedy, Jr., and the Trump Administration for convening two Long COVID roundtables focused on patient experiences and research.
Read More
Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Join Startup Forum Panel at Databricks DATA + AI World Tour in Boston
Published: September 10, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced that Mittul Mehta, Chief Information Officer of Tevogen and Head of Tevogen.AI, will participate as a panelist in the Startup Forum at the Databricks DATA + AI World Tour on October 8, 2025.
Read More
Tevogen Estimates 5-Year Top-Line Revenue of ∼$6.5 Billion For Product Focused on Liver Cancer Prevention with High-Risk Chronic Hepatitis B Infection
Published: September 09, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today shared asset value and potential forecast for the Company's pipeline product, TVGN 116, for liver cancer prevention with high-risk chronic Hepatitis B infections.
Read More
Tevogen Values TVGN-489 at $9–$11 Billion rNPV, Its First Clinical Product From the Proprietary ExacTcell™ Allogeneic T Cell Platform
Published: September 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today shared the risk-adjusted net present value (rNPV) estimate of $9 billion to $11 billion for TVGN-489, an allogeneic precision T cell therapy and the first clinical-stage product from its proprietary ExacTcell™ platform. TVGN-489 is being developed for the treatment of SARS-CoV-2 infection in high-risk vulnerable patients and for Long-COVID in patients with evidence of a persistent viral reservoir.
Read More
Tevogen Shares Valuation of Key Assets and Potential Forecast For Pipeline Product Focused on EBV Associated Leukemia and Lymphomas
Published: September 04, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today shared asset value and potential forecast for the Company's pipeline product, TVGN 930, for treatment of non-solid tumor malignancies stemming from Epstein-Barr Virus (EBV).
Read More
Tevogen Bio Highlights Proprietary Assets and Upcoming Valuation Disclosure
Published: August 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today updated investors of its significant internally developed assets, which under U.S. GAAP accounting rules are not reflected on the Company's balance sheet, yet represent substantial long-term value. Tevogen will provide detailed information and valuation of these assets in the coming days.
Read More
Tevogen Expresses Gratitude to Yale for Recognition of Dr. Ryan Saadi and Company's Mission of Health Equity
Published: August 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today expressed its appreciation to Yale University for recognizing Founder and CEO Dr. Ryan Saadi, MPH '95, and the Company's mission of health equity.
Read More
Tevogen Sees Continued Growth in Institutional Ownership in Q2 2025; 72% of Holders Increased or Maintained Positions
Published: August 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced an update on institutional ownership of the Company's outstanding common stock, as reported by institutional investment managers on Form 13F filed with the Securities and Exchange Commission (SEC).
Read More
Tevogen Recognized in BINJE's BEST Health Care 2025 for Advancing Health Equity and Sustainable Biopharma
Published: August 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., Aug. 22, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or the “Company”) (Nasdaq: TVGN), announced today that it has been named in BINJE's BEST Health Care 2025: Companies, Organizations and Service Providers. BINJE, a media outlet covering business and politics across New Jersey, highlighted Tevogen Bio's Founder and CEO, Ryan Saadi, MD, MPH, for his commitment to health equity and innovation in sustainable biopharma.
Read More
REPEAT -- Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts
Published: August 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
Includes $36 million line of credit and potential $14 million private placement WARREN, N.J., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, following the recent elimination of $94.9 million in balance sheet liabilities, has entered into a definitive agreement for up to $50 million in financing.
Read More
Tevogen Delivers Stronger Second Quarter and First Half 2025 Financial Results with Reduced Expenses and Growth Momentum
Published: August 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or the “Company) (Nasdaq: TVGN) announced its financial results for the fiscal quarter ended June 30, 2025, and filed its Form 10-Q with the Securities and Exchange Commission (“SEC”), highlighting improved operational efficiency.
Read More
Tevogen to Release Internal Asset Valuation; CEO Affirms Assets Are Fully Protected
Published: August 14, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or the “Company”) (Nasdaq: TVGN), today issued the following statement from Ryan Saadi, M.D., M.P.H., Founder and CEO.
Read More
Repeat - Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology
Published: August 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that its artificial intelligence initiative, Tevogen.AI, is expanding its collaboration with Microsoft (Nasdaq: MSFT) and Databricks, to build the beta version of its foundational PredicTcell model.
Read More
Tevogen Bio Reaffirms Investor Confidence with Estimated Asset Value Exceeding $10 Billion
Published: August 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or the “Company) (Nasdaq: TVGN), reiterates investor confidence and estimated asset value over $10 billion.
Read More
REPEAT -- Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast of Nearly $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $18 Billion and $22 Billion
Published: August 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, today announced its top-line revenue forecast for its specialty care pipeline, projecting nearly $1 billion in revenue in its launch year and a cumulative 5-year estimate of between $18 billion and $22 billion. This forecast reflects the company's unique, faster, and cost-efficient drug development model which has the potential to serve as a blueprint to ensure sustainable medical innovation for years to come.
Read More
REPEAT - Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders
Published: August 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today released a letter to stockholders.
Read More
REPEAT - Tevogen Sees Significant Institutional Ownership Growth; 73% of Holders Increase Positions
Published: August 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced an update on institutional ownership of the Company's outstanding common stock, as reported by institutional investment managers on Form 13F filed with the Securities and Exchange Commission (SEC).
Read More
Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology
Published: August 05, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that its artificial intelligence initiative, Tevogen.AI, is expanding its collaboration with Microsoft (Nasdaq: MSFT) and Databricks, to build the beta version of its foundational PredicTcell model.
Read More
Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders
Published: August 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today released a letter to stockholders.
Read More
Tevogen Bio to Accept $1 Million Additional Grant Funding for AI Expansion
Published: August 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or the “Company) (Nasdaq: TVGN), today announced that it expects to receive $1 million in grant funding to advance Tevogen.AI, its artificial intelligence–powered drug discovery and development program.
Read More
Tevogen Highlights 74% Insider Ownership, Reinforcing Long-Term Vision
Published: July 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., July 30, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today highlighted the Company's significant insider ownership of outstanding common stock, as most recently reported on July 10, 2025, on Form 8-K filed with the Securities and Exchange Commission.
Read More
About Tevogen Bio Holdings Inc. (TVGN)
- IPO Date 2022-01-05
- Website https://tevogen.com
- Industry Biotechnology
- CEO Ryan H. Saadi
- Employees 18